Cellular and humoral response to the fourth BNT162b2 mRNA COVID‐19 vaccine dose in patients with CLL
Sign Up to like & getrecommendations! Published in 2022 at "European Journal of Haematology"
DOI: 10.1111/ejh.13878
Abstract: We assessed the humoral and cellular response to the fourth BNT162b2 mRNA COVID‐19 vaccine dose in patients with CLL. A total of 67 patients with CLL and 85 age matched controls tested for serologic response… read more here.
Keywords: response; serologic response; patients cll; vaccine ... See more keywords
COVID-19 in patients with CLL: how can we change the odds?
Sign Up to like & getrecommendations! Published in 2021 at "Blood"
DOI: 10.1182/blood.2021013286
Abstract: In this issue of Blood, Roeker et al report an updated analysis of an international, multicenter study on the outcomes of 374 patients with chronic lymphocytic leukemia (CLL) diagnosed with COVID-19. The current analysis evaluated… read more here.
Keywords: change odds; patients cll; cll change; covid patients ... See more keywords
Efficacy of a third BNT162b2 mRNA COVID-19 vaccine dose in patients with CLL who failed standard 2-dose vaccination
Sign Up to like & getrecommendations! Published in 2021 at "Blood"
DOI: 10.1182/blood.2021014085
Abstract: Patients with chronic lymphocytic leukemia (CLL) have an impaired antibody response to COVID-19 vaccination. Here, we evaluated the antibody response to a third BNT162b2 mRNA vaccine in patients with CLL/small lymphocytic lymphoma (SLL) who failed… read more here.
Keywords: response; patients cll; vaccination; bnt162b2 mrna ... See more keywords
Patients with CLL have a lower risk of death from COVID-19 in the Omicron era
Sign Up to like & getrecommendations! Published in 2022 at "Blood"
DOI: 10.1182/blood.2022016147
Abstract: Previous studies have shown that patients with chronic lymphocytic leukemia (CLL) and corona virus disease 2019 (COVID-19) have high mortality rates. Infection with the omicron variant has been described as a milder disease course in… read more here.
Keywords: omicron; covid; patients cll; risk death ... See more keywords
Hybrid immunity in immunocompromised patients with CLL after SARS-CoV-2 infection followed by booster mRNA vaccination
Sign Up to like & getrecommendations! Published in 2022 at "Blood"
DOI: 10.1182/blood.2022016815
Abstract: Conflict of interest: COI declared see note COI notes: The authors declare no competing financial interests. MB is a consultant for Oxford Immunotech. AS is a consultant for Gritstone Bio, Flow Pharma, Arcturus Therapeutics, ImmunoScape,… read more here.
Keywords: cll sars; hybrid immunity; immunity immunocompromised; immunocompromised patients ... See more keywords
Rare Germline ATM Variants Influence the Development of Chronic Lymphocytic Leukemia
Sign Up to like & getrecommendations! Published in 2022 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.22.00269
Abstract: PURPOSE Germline missense variants of unknown significance in cancer-related genes are increasingly being identified with the expanding use of next-generation sequencing. The ataxia telangiectasia–mutated (ATM) gene on chromosome 11 has more than 1,000 germline missense… read more here.
Keywords: germline atm; atm variants; patients cll; rare germline ... See more keywords
Monitoring and Managing BTK Inhibitor Treatment-Related Adverse Events in Clinical Practice
Sign Up to like & getrecommendations! Published in 2021 at "Frontiers in Oncology"
DOI: 10.3389/fonc.2021.720704
Abstract: Bruton tyrosine kinase (BTK) inhibitors represent an important therapeutic advancement for B cell malignancies. Ibrutinib, the first-in-class BTK inhibitor, is approved by the US FDA to treat patients with chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma… read more here.
Keywords: treatment; patients cll; adverse events; inhibitor ... See more keywords
Poor Neutralizing Antibody Responses in 132 Patients with CLL, NHL and HL after Vaccination against SARS-CoV-2: A Prospective Study
Sign Up to like & getrecommendations! Published in 2021 at "Cancers"
DOI: 10.3390/cancers13174480
Abstract: Simple Summary The urgency of the COVID-19 pandemic has led to accelerated vaccine development within less than a year. Emerging data suggest that the ability of patients with hematological malignancies to form an adequate number… read more here.
Keywords: response; vaccine; patients cll; antibody ... See more keywords
Antibody Response to the SARS-CoV-2 Vaccine and COVID-19 Vulnerability during the Omicron Pandemic in Patients with CLL: Two-Year Follow-Up of a Multicenter Study
Sign Up to like & getrecommendations! Published in 2023 at "Cancers"
DOI: 10.3390/cancers15112993
Abstract: Simple Summary We prospectively analyzed COVID-19 morbidity and severity in 200 consecutive patients with CLL. Increased COVID-19 morbidity was observed in vaccinated patients with CLL. With a median follow-up of 23.4 months, 41% of patients… read more here.
Keywords: response; omicron pandemic; covid; patients cll ... See more keywords